PTC Therapeutics Shared Interim Data From The 12-week Portion Of The PIVOT-HD Phase 2 Study Of PTC 518 In Huntington's Disease Patients, Demonstrating Dose-Dependent Lowering Of Huntingtin Protein Levels In Peripheral Blood Cells
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC 518 in Huntington's disease patients, showing dose-dependent lowering of huntingtin protein levels in peripheral blood cells.
June 21, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PTC Therapeutics' PIVOT-HD Phase 2 study of PTC 518 showed promising results in Huntington's disease patients, potentially boosting the company's stock.
The positive interim data from the PIVOT-HD Phase 2 study of PTC 518 demonstrates the potential effectiveness of the drug in treating Huntington's disease. This news is likely to be seen as a positive development for PTC Therapeutics, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100